Trial Search Results

Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)

This phase I trial studies the side effects and best dose of giving erlotinib and dovitinib together to treat patients with metastatic non-small cell lung cancer. Erlotinib blocks the epidermal growth factor receptor (EGFR) and has known activity in non-small cell lung cancer and dovitinib blocks the fibroblast growth factor receptor (FGFR) and other targets which may be important to treat lung cancer. The combination of both drugs may work better than either drug alone, but may also have increased side effects. This trial will look at the side effects of combining the drugs and look for how effective the combination may be.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Heather Wakelee

Collaborator: Novartis

Stanford Investigator(s):

Intervention(s):

  • Drug: Erlotinib hydrochloride
  • Drug: Dovitinib lactate

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   - Histologically-confirmed metastatic non-small cell lung cancer

   - One or more primary or metastatic lesions measurable in at least one dimension by
   modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria (v1.1) within
   4 weeks prior to entry of study

   - Patients who have failed any number of prior therapies, including those previously
   treated with erlotinib

   - Life expectancy > 2 months

   - Eastern Cooperative Oncology Group (ECOG) performance status 0-2

   - Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (>= 1500/mm^3)

   - Platelets (PLT) >= 100,000/mm^3

   - Hemoglobin (Hgb) >= 9 g/dL

   - Serum creatinine =< 1.5 x upper limit of normal (ULN)

   - Serum bilirubin =< 1.5 x ULN (regardless of whether liver metastases are present at
   baseline)

   - Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and
   alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) =< 3.0 x ULN
   (regardless of whether liver metastases are present at baseline)

   - Ability to understand and the willingness to provide verbal and written informed
   consent

   - Patients - both males and females- with reproductive potential (i.e. menopausal for
   less than 1 year and not surgically sterilized) must practice effective contraceptive
   measures throughout the study; women of childbearing potential must provide a negative
   pregnancy test (serum or urine) within 14 days prior to registration

Exclusion Criteria:

   - Patients who have received the last administration of chemotherapy or immunotherapy =<
   the timeframe defined below after the end of the cycle of the last treatment, prior to
   starting study drug, or who have not recovered from the side effects of such therapy:

      - Patients who have received the last administration of chemotherapy/immunotherapy
      in a daily schedule =< 7 days prior to starting study drug

      - Patients who have received the last administration of chemotherapy/immunotherapy
      in a weekly schedule =< 2 weeks prior to starting study drug

      - Patients who have received the last administration of chemotherapy/immunotherapy
      in a 2-weekly schedule =< 3 weeks prior to starting study drug

      - Patients who have received the last administration of chemotherapy/immunotherapy
      in a 3-weekly schedule =< 4 weeks prior to starting study drug

      - Patients who have received the last administration of chemotherapy/immunotherapy
      in a 4-weekly schedule =< 5 weeks prior to starting study drug

      - Patients who have received the last administration of nitrosourea, mitomycin-C =<
      6 weeks prior to starting study drug, or who have not recovered from the side
      effects of such therapy

   - Patients who have received wide field radiotherapy (including therapeutic
   radioisotopes such as strontium 89) =< 4 weeks or limited field radiation for
   palliation =< 2 weeks prior to starting study drug or who have not recovered from side
   effects of such therapy

   - Patients who have undergone major surgery =< 4 weeks prior to starting study drug or
   who have not recovered from side effects of such therapy

   - If history of other primary cancer, subject will be eligible only if she or he has:

      - Curatively resected non-melanomatous skin cancer, basal cell carcinoma, squamous
      cell carcinoma

      - Curatively treated cervical carcinoma in situ

      - Other primary solid tumor curatively treated with no known active disease present
      and no treatment administered for the last 3 years

   - Subjects known to have chronic or active hepatitis B or C infection with impaired
   hepatic function (ineligible if AST and ALT > 2.5 x ULN)

   - History of any medical or psychiatric condition or laboratory abnormality that in the
   opinion of the investigator may increase the risks associated with study participation
   or study drug administration or may interfere with the conduct of the study or
   interpretation of study results

   - Patients who continue to smoke (given that smoking decreases serum levels of
   erlotinib)

   - Female subject who is breast-feeding or who has positive serum pregnancy test 72 hours
   prior to enrollment

   - Any of the following concurrent severe and/or uncontrolled medical conditions within 6
   months of enrollment which could compromise participation in the study:

      - Unstable angina pectoris

      - Uncontrolled hypertension defined by a systolic blood pressure (SBP) >= 160 mm Hg
      and/or diastolic blood pressure (DBP) >= 100 mm Hg, with or without
      anti-hypertensive medication; initiation or adjustment of antihypertensive
      medication(s) is allowed prior to study entry

      - Left ventricular ejection fraction (LVEF) assessed by 2-D echocardiogram (ECHO) <
      50% or lower limit of normal (whichever is higher) or multiple gated acquisition
      scan (MUGA) < 45% or lower limit of normal (whichever is higher)

      - Myocardial infarction

      - Serious uncontrolled ventricular arrhythmia

      - Clinically significant resting bradycardia

      - Uncontrolled diabetes

      - Transient Ischemic Attach (TIA)

      - Cerebrovascular accident (CVA)

      - Pulmonary embolism (PE)

      - Impairment of gastrointestinal (GI) function or GI disease that may significantly
      alter the absorption of dovitinib (e.g. ulcerative diseases, uncontrolled nausea,
      vomiting, diarrhea, malabsorption syndrome, or small bowel resection)

      - Serious active or uncontrolled infection

      - Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the
      lung

      - Chronic renal disease

      - Cirrhosis, chronic active hepatitis or chronic persistent hepatitis

   - Patients who are currently receiving anticoagulation treatment with therapeutic doses
   of warfarin or enoxaparin

   - Women of child-bearing potential, who are biologically able to conceive, not employing
   two forms of highly effective contraception; highly effective contraception (e.g. male
   condom with spermicide, diaphragm with spermicide, intra-uterine device) must be used
   by both sexes during the study and must be continued for 8 weeks after the end of
   study treatment; oral, implantable, or injectable contraceptives may be affected by
   cytochrome P450 interactions, and are therefore not considered effective for this
   study; women of child-bearing potential, defined as sexually mature women who have not
   undergone a hysterectomy or who have not been naturally postmenopausal for at least 12
   consecutive months (e.g., who has had menses any time in the preceding 12 consecutive
   months), must have a negative serum pregnancy test =< 14 days prior to starting study
   treatment

   - Patients unwilling to or unable to comply with the protocol

   - There may be danger of harm to study participants because of human immunodeficiency
   virus (HIV) comorbidity or drug interactions

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
ccto-office@stanford.edu
650-498-7061
Not Recruiting